| scholarly article | Q13442814 |
| P50 | author | Seyhan Boyoglu-Barnum | Q106368738 |
| Lia M Haynes | Q106464754 | ||
| Ralph A. Tripp | Q45349521 | ||
| Larry J. Anderson | Q61046798 | ||
| P2093 | author name string | Martin L Moore | |
| Kelsey A Gaston | |||
| Patricia Jorquera | |||
| Sean O Todd | |||
| Tatiana Chirkova | |||
| Thomas R Barnum | |||
| P2860 | cites work | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 |
| A novel transcription factor, T-bet, directs Th1 lineage commitment | Q22253874 | ||
| TCR-dependent translational control of GATA-3 enhances Th2 differentiation | Q28290084 | ||
| The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation | Q28584806 | ||
| Control of inflammation, cytokine expression, and germinal center formation by BCL-6 | Q28585541 | ||
| Inhibition of Th2 differentiation and GATA-3 expression by BCL-6 | Q28594529 | ||
| Follicular helper CD4 T cells (TFH) | Q29615063 | ||
| Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis | Q29619821 | ||
| The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. | Q30306426 | ||
| Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. | Q30425776 | ||
| Autocrine regulation of pulmonary inflammation by effector T-cell derived IL-10 during infection with respiratory syncytial virus | Q30431134 | ||
| Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. | Q33648461 | ||
| Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses | Q33754172 | ||
| Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells | Q33760691 | ||
| Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice | Q33797058 | ||
| Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse | Q33807265 | ||
| The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin | Q33863111 | ||
| Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice | Q33920501 | ||
| CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection | Q34055489 | ||
| CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung | Q82244974 | ||
| Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection | Q34072674 | ||
| Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. | Q34120278 | ||
| IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice | Q34185860 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| Respiratory syncytial virus infection in elderly and high-risk adults | Q34414401 | ||
| Biological challenges and technological opportunities for respiratory syncytial virus vaccine development | Q34504791 | ||
| Therapeutic targeting of respiratory syncytial virus G-protein. | Q34603346 | ||
| Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus | Q34647754 | ||
| The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes | Q34651258 | ||
| CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses | Q34726022 | ||
| IFN-α as an Adjuvant for Adenovirus-Vectored FMDV Subunit Vaccine through Improving the Generation of T Follicular Helper Cells | Q34792464 | ||
| Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease | Q34990420 | ||
| The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. | Q34996665 | ||
| Germinal center B cell and T follicular helper cell development initiates in the interfollicular zone | Q35758747 | ||
| Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection | Q35831296 | ||
| Pathogenesis of respiratory syncytial virus infection | Q35848350 | ||
| CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function | Q36368291 | ||
| Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. | Q36400958 | ||
| Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus | Q36401291 | ||
| Treg control of antimicrobial T cell responses | Q36450013 | ||
| Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P | Q36464353 | ||
| Regulatory T cells in virus infections | Q36563550 | ||
| Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review | Q36593301 | ||
| Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells | Q36650105 | ||
| Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. | Q36684360 | ||
| Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity | Q36919232 | ||
| Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells | Q36937131 | ||
| Lck mediates Th2 differentiation through effects on T-bet and GATA-3. | Q36956614 | ||
| Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines | Q36957257 | ||
| Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation | Q37038789 | ||
| T follicular helper (TFH) cells in normal and dysregulated immune responses | Q37049341 | ||
| Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients | Q37118406 | ||
| Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities | Q37127882 | ||
| A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction | Q37157161 | ||
| Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model | Q37192233 | ||
| Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay | Q37203117 | ||
| A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice | Q37252613 | ||
| Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice | Q37252618 | ||
| The host response and molecular pathogenesis associated with respiratory syncytial virus infection | Q37263779 | ||
| HSP70/CD80 DNA vaccine inhibits airway remodeling by regulating the transcription factors T-bet and GATA-3 in a murine model of chronic asthma | Q37321867 | ||
| Follicular helper T cells as cognate regulators of B cell immunity | Q37510254 | ||
| Strategic priorities for respiratory syncytial virus (RSV) vaccine development | Q37572640 | ||
| Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential | Q37670253 | ||
| Multiple functional domains and complexes of the two nonstructural proteins of human respiratory syncytial virus contribute to interferon suppression and cellular location | Q38749026 | ||
| Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced T-cell proliferation by contact | Q39682220 | ||
| Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction. | Q39963611 | ||
| Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. | Q40130924 | ||
| Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay | Q40222017 | ||
| Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women | Q40555244 | ||
| Calfection: a novel gene transfer method for suspension cells. | Q40595125 | ||
| An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine | Q40940832 | ||
| Antigenic analysis of chimeric and truncated G proteins of respiratory syncytial virus | Q41346333 | ||
| Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus | Q43542082 | ||
| CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein | Q43690717 | ||
| Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells | Q44237000 | ||
| Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals | Q44480572 | ||
| Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults | Q44982507 | ||
| Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus | Q45360497 | ||
| Effect of respiratory syncytial virus infection on plasmacytoid dendritic cell regulation of allergic airway inflammation | Q45363605 | ||
| Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice | Q45383435 | ||
| Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus. | Q45385542 | ||
| Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze | Q45387793 | ||
| Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes | Q45610521 | ||
| Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis. | Q45627167 | ||
| Age related differences in humoral immune response to respiratory syncytial virus infection in adults | Q45644291 | ||
| Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis | Q45723625 | ||
| Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naïve T cells | Q45723895 | ||
| Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus | Q45737617 | ||
| Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level | Q45792098 | ||
| Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population | Q45823296 | ||
| Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine | Q45823297 | ||
| Immunity to and frequency of reinfection with respiratory syncytial virus | Q45853042 | ||
| Infectious respiratory syncytial virus (RSV) effectively inhibits the proliferative T cell response to inactivated RSV in vitro | Q45873441 | ||
| Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children | Q45888997 | ||
| Diversity among memory B cells: origin, consequences, and utility. | Q46918689 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 10569-10583 | |
| P577 | publication date | 2014-07-02 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice | |
| P478 | volume | 88 |
| Q40823850 | A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease |
| Q38983251 | A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza |
| Q35893983 | An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice |
| Q92021897 | Antibody development for preventing the human respiratory syncytial virus pathology |
| Q38598484 | Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents? |
| Q92556931 | Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development |
| Q90521301 | Comparisons of Antibody Populations in Different Pre-Fusion F VLP-Immunized Cotton Rat Dams and Their Offspring |
| Q27468870 | Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play |
| Q36256989 | Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. |
| Q91798893 | Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection |
| Q52605312 | Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody. |
| Q64060972 | Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease |
| Q38635643 | Human Genetic Determinants of Viral Diseases |
| Q58566613 | Human Metapneumovirus: Mechanisms and Molecular Targets Used by the Virus to Avoid the Immune System |
| Q90458905 | In vitro model for the assessment of human immune responses to subunit RSV vaccines |
| Q36409517 | Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease |
| Q39154023 | Modulation of the host immune response by respiratory syncytial virus proteins |
| Q36246429 | Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases |
| Q40301155 | Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective |
| Q92083068 | Mutation of Respiratory Syncytial Virus G Protein's CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells |
| Q89884849 | Natural killer cell activation by respiratory syncytial virus-specific antibodies is decreased in infants with severe respiratory infections and correlates with Fc-glycosylation |
| Q116166317 | Structural Characterization of Ectodomain G Protein of Respiratory Syncytial Virus and Its Interaction with Heparan Sulfate: Multi-Spectroscopic and In Silico Studies Elucidating Host-Pathogen Interactions |
| Q36764982 | Synergy of TLR3 and 7 ligands significantly enhances function of DCs to present inactivated PRRSV antigen through TRIF/MyD88-NF-κB signaling pathway. |
| Q41813514 | Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities |
Search more.